Author(s):
Suman Sharma, Deepinder Singh, Ashima Katyal, Paramjeet S. Gill, Surender Jangra, Bhupender Bhardwaj, Usha Bhocal
Email(s):
drsuman101sharma@gmail.com , deephsr@gmail.com , Docak07@gmail.com , pjsgill@rediffmail.com , sjndri@gmail.com , b.bhupender95@gmail.com , ushabhocal@gmail.com
DOI:
10.52711/0974-360X.2024.00006 
Address:
Suman Sharma1, Deepinder Singh2, Ashima Katyal2*, Paramjeet S. Gill3, Surender Jangra4, Bhupender Bhardwaj3, Usha Bhocal3
1Department of Pathology, Post Graduate Institute of Medical Sciences (PGIMS), Rohtak - 124001, India.
2Department of Microbiology, Kalpana Chawla Government Medical College, Karnal, India.
3Department of Microbiology, Post Graduate Institute of Medical Sciences (PGIMS), Rohtak - 124001, India.
4Department of Chemistry and Biochemistry, Sharda School of basic sciences and Research,
Sharda university, Greater Noida, India.
*Corresponding Author
Published In:
Volume - 17,
Issue - 1,
Year - 2024
ABSTRACT:
The data on the poor outcomes of COVID-19 patients pertaining to their comorbidities is scarce in Indian population. We studied 331 COVID-19 patients admitted to PGIMS, Rohtak, of which 106 were with comorbidities and 225 patients without any comorbid conditions (controls). Among 225 patients without comorbidities, the average length of stay in hospital was ~3.9 days, while patients (n=106) with comorbidities stayed for almost double time (average 7.4 days). Among 106 hospitalized patients with comorbidities, 61 (57.4%) received oxygen support, with an average intake of 6.5 L/min of oxygen, while 29 of 225 (12.8%) controls received an average 3.1 L/min of oxygen. Out 106 patients with comorbidities 49 (46.2%) required ICU admission compared to 18 (8%) of 225 controls. The mortality in patients with comorbidities was 35.8% (38/106), which was higher than patients with no comorbidities (5.7%, 13/225). The Kaplan-Meier survival curve indicated poor survival trends in COVID-19 patients with comorbidities, as compared to those without comorbidities. Overall, this study demonstrates that comorbidities, like diabetes, hypertension, chronic cardiac disease, chronic kidney disease, chronic pulmonary, thyroid disorders, etc. are associated with severe COVID-19 disease progression.
Cite this article:
Suman Sharma, Deepinder Singh, Ashima Katyal, Paramjeet S. Gill, Surender Jangra, Bhupender Bhardwaj, Usha Bhocal. Evaluation of outcome of disease in COVID-19 patients with Comorbidities: An experience from a Tertiary Care Center in North India. Research Journal of Pharmacy and Technology. 2024; 17(1):31-6. doi: 10.52711/0974-360X.2024.00006
Cite(Electronic):
Suman Sharma, Deepinder Singh, Ashima Katyal, Paramjeet S. Gill, Surender Jangra, Bhupender Bhardwaj, Usha Bhocal. Evaluation of outcome of disease in COVID-19 patients with Comorbidities: An experience from a Tertiary Care Center in North India. Research Journal of Pharmacy and Technology. 2024; 17(1):31-6. doi: 10.52711/0974-360X.2024.00006 Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-1-6
REFERENCES:
1. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report 73 [Internet]. 2020.https://apps.who.int/iris/handle/10665/331686.
2. Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T et al Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect. 2020;80(6):656-665.http://doi.org/10.1016/j.jinf.2020.03.041.
3. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P et al Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med [Internet]. 2020; 2(8): 1069–76. https://link.springer.com/10.1007/s42399-020-00363-4.
4. Worldometer. COVID-19 CORONAVIRUS PANDEMIC [Internet]. 2021 [cited 2021 Oct 31]. https://www.worldometers.info/coronavirus.
5. Saito S, Asai Y, Matsunaga N, Hayakawa K, Terada M, Ohtsu H et al First and second COVID-19 waves in Japan: A comparison of disease severity and characteristics. J Infect. 2021; 82(4):84-123. https://doi.org/10.1016/j.jinf.2020.10.033.
6. Harsha NS, Santisteban JR, Satish RT, Kumar GS. Analysis of the Evolutionary pattern of SARS-CoV-2 and its implications in the spread of the disease. Research J Pharma and Tech. 2021;14(4):2229-2. https://doi.org/10.52711/0974-360X.2021.00396.
7. Abdi A, Jalilian M, Sarbarzeh PA, Vlaisavljevic Z. Diabetes and COVID-19: A systematic review on the current evidences. Diabetes Res Clin Pract. 2020; 166: 108347. https://doi.org/10.1016/j.diabres.2020.108347.
8. Wang Y, Lu X, Li Y, Chen H, Chen T, Su N et al Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19. Am J Respir Crit Care Med. 2020; 201(11): 1430-4. https://doi.org/10.1164/rccm.202003-0736LE.
9. Ahmad S, Shoaib A, Ali MS, Alam, MS, Alam N, Ali M et al Epidemiology, Risk, Myths, Pharmacotherapeutic Management and Socio- economic Burden due to Novel COVID-19: A Recent Update. Research J Pharma and Tech. 2021; 14(4): 2308-5. https://doi.org/10.52711/0974-360X.2021.00408.
10. Bajgain KT, Badal S, Bajgain BB, Santana MJ. Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature. Am J Infect Control. 2021; 49(2): 238-46. https://doi.org/10.1016/j.ajic.2020.06.213.
11. Gasmi A, Peana M, Pivina L, Srinath S, Gasmi Benahmed A, Semenova Y et al Interrelations between COVID-19 and other disorders. Clin Immunol. 2021; 224: 108651. https://doi.org/10.1016/j.clim.2020.108651.
12. Kuser AK, Tarar SM, Kassid OM,Zayer NH. CNS and COVID-19: Neurological symptoms of Hospitalized Patients with Coronavirus in Iraq: a surveying case sequences study. Research J. Pharm. and Tech. 2020; 13(12): 6291-4. https://doi.org/10.5958/0974-360X.2020.01094.X.
13. Pinki, Rani D, Bajaj H, Singh R. SARS-COV-2 (COVID-19) and role of real time Reverse Transcription Polymerase Chain Reaction (RT-PCR) in its diagnosis. Research J Pharma and Tech. 2021; 14(6): 3437-40. http://doi.org/10.52711/0974-360X.2021.00598.
14. Osibogun A, Balogun M, Abayomi A, Idris J, Kuyinu Y, Odukoya O et al Outcomes of COVID-19 patients with comorbidities in southwest Nigeria. PLoS One. 2021; 16(3): e0248281. https://doi.org/10.1371/journal.pone.0248281.
15. Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y et al Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020; 55(5): 2000547. https://doi.org/10.1183/13993003.00547-2020.
16. Yadam N, Suhasin G. Prediction of COVID-19 severity associated with Pneumonia by chest CT scan and Serological results. Asian J Pharma and Tech. 2021; 11(3): 198-2. https://doi.org/10.52711/2231-5713.2021.00032.
17. Njenga MK, Dawa J, Nanyingi M, Gachohi J, Ngere I, Letko M et al Why is There Low Morbidity and Mortality of COVID-19 in Africa? Am J Trop Med Hyg. 2020; 103(2): 564-9. https://doi.org/10.4269/ajtmh.20-0474.
18. Shah P, Owens J, Franklin J, Mehta A, Heymann W, Sewell W et al Demographics, comorbidities and outcomes in hospitalized COVID-19 patients in rural southwest Georgia. Ann Med. 2020; 52(7): 354-60. https://doi.org/10.1080/07853890.2020.1791356.
19. Wang Z, Deng H, Ou C, Liang J, Wang Y, Jiang M et al Clinical symptoms, comorbidities and complications in severe and non-severe patients with COVID-19. Medicine (Baltimore). 2020; 99(48): e23327. https://doi.org/10.1097/md.0000000000023327.
20. Padmavathy K M, Rohith S S, Noorzaid M, Rehanna M. Praxis of Technology and Tools in COVID-19 Response. Research J Pharma and Tech. 2021; 14(9): 4808-4.https://doi.org/10.52711/0974-360X.2021.00836.
21. Mor S, Saini P, Wangnoo SK, Bawa T. Worldwide spread of COVID-19 Pandemic and risk factors among Co-morbid conditions especially Diabetes Mellitus in India. Research J. Pharm. and Tech. 2020; 13(5): 2530-2. https://doi.org/10.5958/0974-360X.2020.00450.3.
22. Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID-19 pandemic: a global health crisis. Physiol Genomics. 2020; 52(11): 549-57. http://doi.org/10.1152/physiolgenomics.00089.2020.
23. Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr Clin Res Rev. 2020; 14(3): 247-50. https://doi.org/10.1016/j.dsx.2020.03.013.
24. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020; 17(5): 259–60. https://doi.org/10.1038/s41569-020-0360-5.
25. Singh AK, Misra A. Impact of COVID-19 and comorbidities on health and economics: Focus on developing countries and India. Diabetes Metab Syndr Clin Res Rev. 2020; 14(6): 1625-30. https://doi.org/10.1016%2Fj.dsx.2020.08.032.
26. Kumar A, Kalra Y, Guan WW, Tibrewal V, Batta R, Chen A. COVID-19 impact on excess deaths of various causes in the United States. Ann GIS. 2021;28:457-78.https://doi.org/10.1080/19475683.2021.1982001.
27. Kishor RS, Ramhari BM. Introduction to Covid-19. Research J. Science and Tech. 2020; 12(4): 338-45. http://doi.org/10.5958/2349-2988.2020.00051.0.
28. Swärd P, Edsfeldt A, Reepalu A, Jehpsson L, Rosengren BE, Karlsson MK. Age and sex differences in soluble ACE2 may give insights for COVID-19. Crit Care. 2020; 2(1): 221. https://doi.org/10.1186/s13054-020-02942-2.
29. Saber S, Khodir AE, Maghmomeh AO, Nouh NA, El-Baz AM. COVID-19 Pandemic: current Challenges and future Perspectives. Research J. Pharma. and Tech. 2022; 15(1): 329-7. https://doi.org/10.52711/0974-360x.2022.00054.
30. DebnathS, Saha J. Coronavirus disease (COVID-19): A global threat. Asian J. Pharma. and Tech. 2022; 12(1): 63-9. http://doi.org/10.52711/2231-5713.2022.00011.